{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:16:17Z","timestamp":1780499777379,"version":"3.54.1"},"update-to":[{"DOI":"10.12688\/gatesopenres.13191.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000}},{"DOI":"10.12688\/gatesopenres.13191.2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000}}],"reference-count":27,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1116635"],"award-info":[{"award-number":["OPP1116635"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gatesopenresearch.org"],"crossmark-restriction":false},"short-container-title":["Gates Open Res"],"abstract":"<ns3:p>\n                    <ns3:bold>Background:<\/ns3:bold>\n                    QuantiFERON-TB-Gold-in-tube (QFT-GIT) is an interferon-gamma release assay (IGRA) used to diagnose latent tuberculosis infection. Limited data exists on performance of QuantiFERON-TB Gold-Plus (QFT-Plus), a next generation of IGRA that includes an additional antigen tube 2 (TB2) while excluding TB7.7 from antigen tube 1 (TB1), to measure TB specific CD4+ and CD8+ T lymphocytes responses. We compared agreement between QFT-Plus and QFT-GIT among highly TB exposed goldminers in South Africa.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Methods:<\/ns3:bold>\n                    We enrolled HIV-negative goldminers in South Africa, aged \u226533 years with no prior history of TB disease or evidence of silicosis. Blood samples were collected for QFT-GIT and QFT-Plus. QFT-GIT was considered positive if TB1 tested positive; while QFT-Plus was positive if both or either TB1 or TB2 tested positive, as per manufacturer's recommendations. We compared the agreement between QFT-Plus and QFT-GIT using Cohen\u2019s Kappa. To assess the specific contribution of CD8+ T-cells, we used TB2\u2212TB1 differential values as an indirect estimate. A cut-off value was set at 0.6. Logistic regression was used to identify factors associated with having TB2-TB1&gt;0.6 difference on QFT-Plus.\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Results:<\/ns3:bold>\n                    Of 349 enrolled participants, 304 had QFT-Plus and QFT-GIT results: 205 (68%) were positive on both assays; 83 (27%) were negative on both assays while 16 (5%) had discordant results. Overall, there was 94.7% (288\/304) agreement between QFT-Plus and QFT-GIT (Kappa = 0.87). 214 had positive QFT-Plus result, of whom 202 [94.4%, median interquartile range (IQR): 3.06 (1.31, 7.00)] were positive on TB1 and 205 [95.8%, median (IQR): 3.25 (1.53, 8.02)] were positive on TB2. A TB2-TB1&gt;0.6 difference was observed in 16.4% (35\/214), with some evidence of a difference by BMI; 14.9% (7\/47), 9.8% (9\/92) and 25.3% (19\/75) for BMI of 18.5-24.9, 18.5-25 and &gt;30 kg\/m 2, respectively (P=0.03).\n                  <\/ns3:p>\n                  <ns3:p>\n                    <ns3:bold>Conclusion:<\/ns3:bold>\n                    In a population of HIV-negative goldminers, QFT-Plus showed high agreement with QFT-GIT, suggesting similar performance.\n                  <\/ns3:p>","DOI":"10.12688\/gatesopenres.13191.3","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T08:15:09Z","timestamp":1660810509000},"page":"66","update-policy":"https:\/\/doi.org\/10.12688\/gatesopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing QuantiFERON-TB Gold Plus with QuantiFERON-TB Gold in-tube for diagnosis of latent tuberculosis infection among highly TB exposed gold miners in South Africa"],"prefix":"10.12688","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0752-3192","authenticated-orcid":false,"given":"Thobani","family":"Ntshiqa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1444-9266","authenticated-orcid":false,"given":"Violet","family":"Chihota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-5859","authenticated-orcid":false,"given":"Raoul","family":"Mansukhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindiwe","family":"Nhlangulela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavindhran","family":"Velen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Charalambous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pholo","family":"Maenetje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Hawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-5195","authenticated-orcid":false,"given":"Alison D.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Churchyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"ref-1","article-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management.","year":"2018"},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"185-96","DOI":"10.1093\/oxfordjournals.aje.a120069","article-title":"Aerial Dissemination Of Pulmonary Tuberculosis A Two-Year Study Of Contagion In A Tuberculosis Ward.","volume":"70","author":"R Riley","year":"1959","journal-title":"Am J Epidemiol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"183-201","DOI":"10.1017\/s0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection.","volume":"119","author":"E Vynnycky","year":"1997","journal-title":"Epidemiol Infect."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"3-20","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection.","volume":"27","author":"M Pai","year":"2014","journal-title":"Clin Microbiol Rev."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"e00614-18","DOI":"10.1128\/JCM.00614-18","article-title":"Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.","volume":"56","author":"E Theel","year":"2018","journal-title":"J Clin Microbiol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"2844-50","DOI":"10.1128\/JCM.02411-05","article-title":"Sensitivity Analysis and Potential Uses of a Novel Gamma Interferon Release Assay for Diagnosis of Tuberculosis.","volume":"44","author":"S Tsiouris","year":"2006","journal-title":"J Clin Microbiol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1099-104","DOI":"10.1016\/s0140-6736(00)02742-2","article-title":"Specific immune-based diagnosis of tuberculosis.","volume":"356","author":"P Andersen","year":"2000","journal-title":"Lancet."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"30617","DOI":"10.1038\/srep30617","article-title":"Evaluation of QuantiFERON-TB Gold Plus for Detection of Mycobacterium tuberculosis infection in Japan.","volume":"6","author":"L Yi","year":"2016","journal-title":"Sci Rep."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"206-11","DOI":"10.1164\/rccm.201203-0430OC","article-title":"Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice.","volume":"187","author":"J Metcalfe","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-10","article-title":"Data set for the comparison of the performance of QuantiFERON-TB Gold Plus with QuantiFERON-T Gold in-tube among highly TB exposed gold miners in South Africa.","author":"K Fielding","year":"2020"},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"690-6","DOI":"10.5588\/ijtld.16.0764","article-title":"The sensitivity of the QuantiFERON\u00ae-TB Gold Plus assay in Zambian adults with active tuberculosis.","volume":"21","author":"L Telisinghe","year":"2017","journal-title":"Int J Tuberc Lung Dis."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1650-7","DOI":"10.1128\/JCM.02498-16","article-title":"Evaluation of QuantiFERON-TB Gold-Plus in Health Care Workers in a Low-Incidence Setting.","volume":"55","author":"H Moon","year":"2017","journal-title":"J Clin Microbiol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"701-3","DOI":"10.1016\/j.cmi.2016.05.006","article-title":"Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT.","volume":"22","author":"H Hoffmann","year":"2016","journal-title":"Clin Microbiol Infect."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1411-9","DOI":"10.1183\/13993003.00510-2016","article-title":"First evaluation of QuantiFERON-TB Gold Plus performance in contact screening.","volume":"48","author":"L Barcellini","year":"2016","journal-title":"Eur Respir J."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"38-43","DOI":"10.1016\/j.tube.2017.06.002","article-title":"Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis.","volume":"106","author":"E Petruccioli","year":"2017","journal-title":"Tuberculosis (Edinb)."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"2241-50","DOI":"10.1097\/QAD.0b013e3283117f18","article-title":"Potent immune responses of Ag-specific Vgamma2Vdelta2+ T cells and CD8+ T cells associated with latent stage of Mycobacterium tuberculosis coinfection in HIV-1-infected humans.","volume":"22","author":"L Shao","year":"2008","journal-title":"AIDS."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"e37851","DOI":"10.1371\/journal.pone.0037851","article-title":"QuantiFERON\u00ae-TB Gold In-Tube Performance for Diagnosing Active Tuberculosis in Children and Adults in a High Burden Setting.","volume":"7","author":"M Rose","year":"2012","journal-title":"PLoS One."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"e32482","DOI":"10.1371\/journal.pone.0032482","article-title":"Interferon-\u03b3 Release Assays for the Diagnosis of Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic Review and Meta-Analysis.","volume":"7","author":"M Santin","year":"2012","journal-title":"PLoS One."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"e43790","DOI":"10.1371\/journal.pone.0043790","article-title":"Within-Subject Interlaboratory Variability of QuantiFERON-TB Gold In-Tube Tests.","volume":"7","author":"W Whitworth","year":"2012","journal-title":"PLoS One."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1170-5","DOI":"10.1128\/CVI.00168-09","article-title":"Short-Term Reproducibility of a Commercial Interferon Gamma Release Assay.","volume":"16","author":"A Detjen","year":"2009","journal-title":"Clin Vaccine Immunol."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"845-50","DOI":"10.1128\/JCM.02803-15","article-title":"Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability?","volume":"54","author":"N Banaei","year":"2016","journal-title":"J Clin Microbiol."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1568-77","DOI":"10.1002\/eji.201243262","article-title":"Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease.","volume":"43","author":"V Rozot","year":"2013","journal-title":"Eur J Immunol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"2222-32","DOI":"10.4049\/jimmunol.1101122","article-title":"Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load.","volume":"187","author":"C Day","year":"2011","journal-title":"J Immunol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"1346-52","DOI":"10.1164\/rccm.200306-837OC","article-title":"Mycobacterium tuberculosis\u2013specific CD8+ T Cells Preferentially Recognize Heavily Infected Cells.","volume":"168","author":"D Lewinsohn","year":"2003","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"533-45","DOI":"10.1016\/j.jinf.2014.06.009","article-title":"Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients.","volume":"69","author":"T Chiacchio","year":"2014","journal-title":"J Infect."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"206-12","DOI":"10.1164\/rccm.201107-1355OC","article-title":"CD8+ T Cells Provide an Immunologic Signature of Tuberculosis in Young Children.","volume":"185","author":"C Lancioni","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1587-90","DOI":"10.1183\/13993003.02033-2015","article-title":"First independent evaluation of QuantiFERON-TB Plus performance.","volume":"47","author":"L Barcellini","year":"2016","journal-title":"Eur Respir J."}],"container-title":["Gates Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/gatesopenresearch.org\/articles\/5-66\/v3\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/gatesopenresearch.org\/articles\/5-66\/v3\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/gatesopenresearch.org\/articles\/5-66\/v3\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T09:25:17Z","timestamp":1691400317000},"score":1,"resource":{"primary":{"URL":"https:\/\/gatesopenresearch.org\/articles\/5-66\/v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":27,"URL":"https:\/\/doi.org\/10.12688\/gatesopenres.13191.3","relation":{"has-review":[{"id-type":"doi","id":"10.21956\/gatesopenres.15091.r32392","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/gatesopenres.15091.r34041","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/gatesopenres.15091.r34036","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/gatesopenres.15091.r34041","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/gatesopenres.15091.r32392","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/gatesopenres.15091.r34036","asserted-by":"object"}]},"ISSN":["2572-4754"],"issn-type":[{"value":"2572-4754","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"Indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/5-66\/v3#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/gatesopenres.15091.r32392, Mark Hatherill, South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town, Cape Town, 25 Aug 2022, version 3, indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/5-66\/v3#referee-response-32392","order":0,"name":"referee-response-32392","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/gatesopenres.15091.r34036, Lucia Barcellini, University of Milan, Milan, 02 Aug 2023, version 3, indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/5-66\/v3#referee-response-34036","order":1,"name":"referee-response-34036","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/gatesopenres.15091.r34041, Sonali Sarkar, JIPMER, Puducherry, 07 Aug 2023, version 3, indexed","URL":"https:\/\/gatesopenresearch.org\/articles\/5-66\/v3#referee-response-34041","order":2,"name":"referee-response-34041","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This study was funded by the Bill & Melinda Gates Foundation [OPP1116635]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}